Cargando…
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474456/ https://www.ncbi.nlm.nih.gov/pubmed/28674498 http://dx.doi.org/10.3389/fphar.2017.00382 |
_version_ | 1783244447426805760 |
---|---|
author | Mazorra, Zaima Lavastida, Anabel Concha-Benavente, Fernando Valdés, Anet Srivastava, Raghvendra M. García-Bates, Tatiana M. Hechavarría, Esperanza González, Zuyen González, Amnely Lugiollo, Martha Cuevas, Iván Frómeta, Carlos Mestre, Braulio F. Barroso, Maria C. Crombet, Tania Ferris, Robert L. |
author_facet | Mazorra, Zaima Lavastida, Anabel Concha-Benavente, Fernando Valdés, Anet Srivastava, Raghvendra M. García-Bates, Tatiana M. Hechavarría, Esperanza González, Zuyen González, Amnely Lugiollo, Martha Cuevas, Iván Frómeta, Carlos Mestre, Braulio F. Barroso, Maria C. Crombet, Tania Ferris, Robert L. |
author_sort | Mazorra, Zaima |
collection | PubMed |
description | Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s capacity of killing tumor cells by antibody dependent cellular cytotoxicity (ADCC) and to induce an immune response in cancer patients have not been studied. ADCC-induced by nimotuzumab was determined using a (51)Cr release assay. The in vitro effect of nimotuzumab on natural killer (NK) cell activation and dendritic cell (DC) maturation and the in vivo frequency of circulating regulatory T cells (Tregs) and NK cells were assessed by flow cytometry. Cytokine levels in supernatants were determined by ELISA. ELISpot was carried out to quantify EGFR-specific T cells in nimotuzumab-treated head and neck cancer (HNSCC) patients. Nimotuzumab was able to kill EGFR+ tumor cells by NK cell-mediated ADCC. Nimotuzumab-activated NK cells promoted DC maturation and EGFR-specific CD8+ T cell priming. Interestingly, nimotuzumab led to upregulation of some immune checkpoint molecules on NK cells (TIM-3) and DC (PD-L1), to a lower extent than another EGFR mAb, cetuximab. Furthermore, circulating EGFR-specific T cells were identified in nimotuzumab-treated HNSCC patients. Notably, nimotuzumab combined with cisplatin-based chemotherapy and radiation increased the frequency of peripheral CD4+CD39+FOXP3+Tregs which otherwise were decreased to baseline values when nimotuzumab was used as monotherapy. The frequency of circulating NK cells remained constant during treatment. Nimotuzumab-induced, NK cell-mediated DC priming led to induction of anti-EGFR specific T cells in HNSCC patients. The association between EGFR-specific T cells and patient clinical benefit with nimotuzumab treatment should be investigated. |
format | Online Article Text |
id | pubmed-5474456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54744562017-07-03 Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients Mazorra, Zaima Lavastida, Anabel Concha-Benavente, Fernando Valdés, Anet Srivastava, Raghvendra M. García-Bates, Tatiana M. Hechavarría, Esperanza González, Zuyen González, Amnely Lugiollo, Martha Cuevas, Iván Frómeta, Carlos Mestre, Braulio F. Barroso, Maria C. Crombet, Tania Ferris, Robert L. Front Pharmacol Pharmacology Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s capacity of killing tumor cells by antibody dependent cellular cytotoxicity (ADCC) and to induce an immune response in cancer patients have not been studied. ADCC-induced by nimotuzumab was determined using a (51)Cr release assay. The in vitro effect of nimotuzumab on natural killer (NK) cell activation and dendritic cell (DC) maturation and the in vivo frequency of circulating regulatory T cells (Tregs) and NK cells were assessed by flow cytometry. Cytokine levels in supernatants were determined by ELISA. ELISpot was carried out to quantify EGFR-specific T cells in nimotuzumab-treated head and neck cancer (HNSCC) patients. Nimotuzumab was able to kill EGFR+ tumor cells by NK cell-mediated ADCC. Nimotuzumab-activated NK cells promoted DC maturation and EGFR-specific CD8+ T cell priming. Interestingly, nimotuzumab led to upregulation of some immune checkpoint molecules on NK cells (TIM-3) and DC (PD-L1), to a lower extent than another EGFR mAb, cetuximab. Furthermore, circulating EGFR-specific T cells were identified in nimotuzumab-treated HNSCC patients. Notably, nimotuzumab combined with cisplatin-based chemotherapy and radiation increased the frequency of peripheral CD4+CD39+FOXP3+Tregs which otherwise were decreased to baseline values when nimotuzumab was used as monotherapy. The frequency of circulating NK cells remained constant during treatment. Nimotuzumab-induced, NK cell-mediated DC priming led to induction of anti-EGFR specific T cells in HNSCC patients. The association between EGFR-specific T cells and patient clinical benefit with nimotuzumab treatment should be investigated. Frontiers Media S.A. 2017-06-19 /pmc/articles/PMC5474456/ /pubmed/28674498 http://dx.doi.org/10.3389/fphar.2017.00382 Text en Copyright © 2017 Mazorra, Lavastida, Concha-Benavente, Valdés, Srivastava, García-Bates, Hechavarría, González, González, Lugiollo, Cuevas, Frómeta, Mestre, Barroso, Crombet and Ferris. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Mazorra, Zaima Lavastida, Anabel Concha-Benavente, Fernando Valdés, Anet Srivastava, Raghvendra M. García-Bates, Tatiana M. Hechavarría, Esperanza González, Zuyen González, Amnely Lugiollo, Martha Cuevas, Iván Frómeta, Carlos Mestre, Braulio F. Barroso, Maria C. Crombet, Tania Ferris, Robert L. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
title | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
title_full | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
title_fullStr | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
title_full_unstemmed | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
title_short | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
title_sort | nimotuzumab induces nk cell activation, cytotoxicity, dendritic cell maturation and expansion of egfr-specific t cells in head and neck cancer patients |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474456/ https://www.ncbi.nlm.nih.gov/pubmed/28674498 http://dx.doi.org/10.3389/fphar.2017.00382 |
work_keys_str_mv | AT mazorrazaima nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT lavastidaanabel nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT conchabenaventefernando nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT valdesanet nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT srivastavaraghvendram nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT garciabatestatianam nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT hechavarriaesperanza nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT gonzalezzuyen nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT gonzalezamnely nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT lugiollomartha nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT cuevasivan nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT frometacarlos nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT mestrebrauliof nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT barrosomariac nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT crombettania nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients AT ferrisrobertl nimotuzumabinducesnkcellactivationcytotoxicitydendriticcellmaturationandexpansionofegfrspecifictcellsinheadandneckcancerpatients |